Lynn A. Tetrault's Insider Trades & SAST Disclosures
Lynn A. Tetrault's most recent trade in Rhythm Pharmaceuticals Inc. was a trade of 10,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Sept. 9, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Lynn A. Tetrault.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.15 per share. | 09 Sep 2024 | 10,000 | 13,000 (0%) | 0% | 4.2 | 41,500 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Sale of securities on an exchange or to another person at price $ 50.20 per share. | 09 Sep 2024 | 8,661 | 3,350 (0%) | 0% | 50.2 | 434,796 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Sale of securities on an exchange or to another person at price $ 49.05 per share. | 09 Sep 2024 | 8,490 | 12,011 (0%) | 0% | 49.0 | 416,418 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 7,501 | 0 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.99 per share. | 09 Sep 2024 | 7,501 | 20,501 (0%) | 0% | 19.0 | 142,444 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Sale of securities on an exchange or to another person at price $ 50.04 per share. | 09 Sep 2024 | 3,199 | 3,000 (0%) | 0% | 50.0 | 160,068 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.99 per share. | 09 Sep 2024 | 3,199 | 6,199 (0%) | 0% | 19.0 | 60,749 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 3,199 | 7,501 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Sale of securities on an exchange or to another person at price $ 50.60 per share. | 09 Sep 2024 | 350 | 3,000 (0%) | 0% | 50.6 | 17,710 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 4,300 | 10,700 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Sale of securities on an exchange or to another person at price $ 50.01 per share. | 26 Aug 2024 | 4,300 | 3,000 (0%) | 0% | 50.0 | 215,029 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.99 per share. | 26 Aug 2024 | 4,300 | 7,300 (0%) | 0% | 19.0 | 81,657 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.15 per share. | 12 Aug 2024 | 10,000 | 13,000 (0%) | 0% | 4.2 | 41,500 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Sale of securities on an exchange or to another person at price $ 44.62 per share. | 12 Aug 2024 | 9,593 | 3,407 (0%) | 0% | 44.6 | 427,996 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Sale of securities on an exchange or to another person at price $ 45.37 per share. | 12 Aug 2024 | 407 | 3,000 (0%) | 0% | 45.4 | 18,466 | Common Stock |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 0 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 61,398 (0%) | 0% | 0 | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 3,000 | 0 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 3,000 | 3,000 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Acelyrin Inc | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 43,680 | 43,680 | - | - | Director Stock Option (right to buy) | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 12,254 | 12,254 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 8,672 | 8,672 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Sale of securities on an exchange or to another person at price $ 15.97 per share. | 04 Mar 2024 | 6,112 | 50,062 (0%) | 0% | 16.0 | 97,579 | Common Stock |
| Acelyrin Inc | Tetrault A. Lynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 89,955 | 89,955 | - | - | Director Stock Option (right to buy) | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 3,000 | 3,000 | - | - | Restricted Stock Units | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.60 per share. | 22 May 2023 | 1,507 | 56,174 (0%) | 0% | 11.6 | 17,481 | Common Stock |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2023 | 1,507 | 0 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,556 | 54,667 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 13,882 | 13,882 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2022 | 3,334 | 0 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 18 May 2022 | 3,334 | 39,111 (0%) | 0% | 7.3 | 24,238 | Common Stock |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2021 | 972 | 972 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2021 | 838 | 35,777 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2021 | 1,389 | 0 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.11 per share. | 11 Jun 2021 | 1,389 | 34,939 (0%) | 0% | 9.1 | 12,654 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 3,448 | 3,448 | - | - | Stock Options (Right to Buy) | |
| Neogenomics Inc. | Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,698 | 44,351 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges